← Back to Search

Device

Monitoring Atrial Fibrillation After COVID-19 (unCOVer-AF Trial)

N/A
Waitlist Available
Led By Andrea Natale, MD
Research Sponsored by Texas Cardiac Arrhythmia Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

This trial is looking at the natural history of atrial fibrillation (AF) in patients who have had their first arrhythmic episode during COVID-19 hospitalization.

Who is the study for?
This trial is for adults over 18 who had their first episode of atrial fibrillation during COVID-19 hospitalization. They must have a confirmed SARS-CoV-2 infection and either already have or get an ILR, PMK, or ICD device implanted. People with a history of AF, severe heart valve issues, kidney failure on dialysis, or conditions that could risk their safety can't join.Check my eligibility
What is being tested?
The study is tracking the progression of atrial fibrillation in patients who experienced it for the first time while hospitalized with COVID-19. It uses devices like ILRs (implantable loop recorders), PMKs (pacemakers), and ICDs (implantable cardioverter-defibrillators) to monitor heart rhythm continuously.See study design
What are the potential side effects?
While this study focuses on observation rather than treatment, implanting devices like ILRs, PMKs, and ICDs can cause risks such as infection at the site of implantation, bleeding, pain at the implant site, and potential malfunction of the device.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AF Burden
AF Progression
Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism
Secondary outcome measures
Composite of all-cause mortality, stroke and bleeding
Time to adjudicated cardiovascular death

Trial Design

1Treatment groups
Experimental Treatment
Group I: COVID-19 patients with new-onset AFExperimental Treatment1 Intervention
Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.

Find a Location

Who is running the clinical trial?

Texas Cardiac Arrhythmia Research FoundationLead Sponsor
37 Previous Clinical Trials
13,180 Total Patients Enrolled
26 Trials studying Atrial Fibrillation
6,445 Patients Enrolled for Atrial Fibrillation
Domenico G Della Rocca, MDStudy DirectorTexas Cardiac Arrhythmia Research Foundation
Andrea Natale, MDPrincipal InvestigatorTexas Cardiac Arrhythmia Research Foundation
35 Previous Clinical Trials
8,018 Total Patients Enrolled
26 Trials studying Atrial Fibrillation
7,239 Patients Enrolled for Atrial Fibrillation

Media Library

ICD (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04830774 — N/A
Atrial Fibrillation Research Study Groups: COVID-19 patients with new-onset AF
Atrial Fibrillation Clinical Trial 2023: ICD Highlights & Side Effects. Trial Name: NCT04830774 — N/A
ICD (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04830774 — N/A
~47 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top